Verve Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€51.15M - Cost of goods sold
€0.00 - Gross profit
€51.15M - SG&A expenses
€49.45M - R&D expenses
€180.55M - EBITDA
-€172.99M - D&A
€5.87M - EBIT
-€178.85M - Interest expenses
€0.00 - EBT
-€155.03M - Tax expenses
€276.28K - Net income
-€155.30M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€4.04M - Changes in working capital
-€6.58M - Operating cash flow
-€122.23M - Capex
€3.88M - Other investing cash flow
€0.00 - Net investing cash flow
€58.64M - Total cash dividends paid
€0.00 - Issuance of common stock
€20.81M - Debt repayment
€0.00 - Other financing cash flow
€1.90M - Net financing cash flow
€22.71M - Foreign exchange effects
€0.00 - Net change in cash
-€40.88M - Cash at end of period
€86.94M - Free cash flow
-€118.34M
Balance sheet
- Cash and cash equivalents
€82.84M - Cash and short-term investments
€426.49M - Total receivables
€1.20M - Inventory
€0.00 - Other current assets
€11.30M - Total current assets
€439.00M - Property, plant & equipment
€81.23M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€6.73M - Total non-current assets
€87.96M - Total assets
€526.95M - Accounts payable
€4.59M - Short-term debt
€9.02M - Other current liabilities
€14.63M - Total current liabilities
€44.60M - Long-term debt
€49.87M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€882.88K - Total non-current liabilities
€76.08M - Total liabilities
€120.68M - Common stock
€76.36K - Retained earnings
-€664.13M - Other equity
€337.19K - Total equity
€406.27M - Total liabilities and shareholders' equity
€526.95M
Company information
- Market capitalization
€859.19M - Employees
274 - Enterprise Value
€541.71M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -19,566.2% - EBITDA margin
-
-338.2% Much better than peer group: -26,577.3% - EBIT margin
-
-349.7% Much better than peer group: -26,317.3% - EBT margin
-
-303.1% Much better than peer group: -31,223.0% - Net margin
-
-303.6% Much better than peer group: -31,192.0% - ROE
-
-38.2% Better than peer group: -51.0% - ROA
-
-29.5% Better than peer group: -34.7% - Asset turnover
-
9.7% Even with peer group: 7.6% - FCF margin
-
-246.6% Much better than peer group: -20,592.3% - FCF yield
-14.7% - Efficiency ratio
438.2% - Net sales per employee
-
€186.67K - Net income per employee
-
-€566.80K